Abbott (formerly Knoll) is developing darusentan, an endothelin A antagonist, as a potential treatment for congestive heart failure (CHF) . The compound entered phase II trials in December 1998 . In a model of monocrotaline-induced pulmonary hypertension, darusentan (50 mg/kg/day), significantly reduced right ventricular systolic pressure, and in a canine model of CHF chronic treatment for 2 weeks significantly reduced left ventricular end diastolic pressure, mean pulmonary artery pressure, and right atrial pressure. Darusentan is a selective antagonist in vitro (ET(A): K(i) = 1.4 nM; ET(B): K(i) = 184 nM) .
|Number of pages||9|
|Journal||I Drugs: The Investigational Drugs Journal|
|Publication status||Published - 1 Nov 2001|